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perspective are c5,325 (±9588), c18,045c (±34487) and c41,716 (±35211) at mild, 
moderate and severe stages respectively in France; c3,125 (±4319), c8,457 (±18374) 
and c5,069 (±11747) in Italy. Associated EQ-5D utilities are respectively 0.79 (±0.18), 
0.39 (±0.37), −0.11 (±0.3) in France; 0.59 (±0.44), 0.39 (±0.42), 0.25 (±0.44) in Italy. 
The primary cost driver is productivity loss. In France, hospitalization and nursing 
home costs are the main components of direct costs. For more severely affected patients, 
medical resource utilization diminishes while caregiver involvement increases signiﬁ -
cantly (the shift is greater in Italy than France). Physical, mental and social HRQoL 
domains are all seriously affected. CONCLUSIONS: Euro-HDB is the ﬁ rst study to 
comprehensively assess the cost and HRQOL burden of HD. The 1:5 cost ratio 
(Italy : France) is consistent across most of the cost items, suggesting that differences in 
health care systems, access to health care and cultural attitudes towards caring for 
patients at home have a large impact on a country’s overall costs. Results suggest that 
HD has greater impact on HRQOL than Parkinson’s disease and Alzheimer’s disease.
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The economic burden of Multiple Sclerosis (MS) on society and the individuals con-
cerned is not known. Documenting such costs is essential for several reasons: costs of 
illness is a key factor of optimal disease management policies, knowledge of cost is 
useful for allocating research and development. The aim of our study as the ﬁ rst 
pharmacoeconomic investigation in Iran was to estimate the costs of multiple sclerosis 
according to severity of disease. Total, direct and indirect costs were compared in 160 
patients divided into three groups categorized by disease severity: stage I Expanded 
Disability Status Scale (EDSS < 2.5), stage II (EDSS 3–4.5) and stage III (EDSS > 5). 
The majority of these patients (94%) developed relapsing- remitting MS. a minority 
of the patients (0.2–4%) developed secondary progressive and primary progressive 
MS. Cost evaluation was performed from the societal perspective and covered the 
one-year period. The study was carried out at the Division of Neurology at Ghaem 
Hospital and MS association in Mashhad in northeast of Iran and was approved by 
the local ethics committee. The mean total cost/patient for one year was estimated at 
$27,095, $27,997and $31,662 for stage I, II and III, respectively. Both direct and 
indirect costs increased with MS progression. For indirect cost the main item was 
productivity loss. The mean extra medicine (treatments for MS symptoms and adverse 
effects of medications) cost/patient for one year was calculated at $19,036. This study 
conﬁ rms that MS represents a high economic burden to patients and society, with 
direct costs greatly exceeding indirect costs. As costs increase with disease progression, 
treatment efforts should focus on patients in the early stages of MS. Disease support 
system that monitors a variety of common progressive signs for the MS individuals is 
a key element of a management program as well.
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OBJECTIVES: According to EU-guidelines testing all patients on interferon-beta 
(IFNb) for presence of neutralizing antibodies (NAB) is recommended irrespective of 
clinical course and stop IFNb or switch to alternatives in patients who developed 
persistent NAB; based on the fact that development in persistently NAB-positive 
patients equals that of placebo-treated patients. Economic impact of NAB-testing in 
MS-patients has not been explored yet. METHODS: This analysis estimated the 
economic impact of NAB-testing versus not testing during IFNb treatment in MS-
patients (n = 3590) on Austria’s health care system. a cost of illness model (decision 
tree combined with an integrated Markov model, time horizon 5 years), based on the 
cohort of IFNb-treated patients was performed. Two alternatives were compared: 
Cost-effectiveness of NAB-testing versus no NAB-testing. The NAB-testing arm 
allowed switching to alternative therapies whereas no-NAB-testing did not. Direct 
costs comprised all treatment-costs of symptoms due to MS. Indirect costs were not 
included. All costs represent data from 2010 (discounted at 5%p.a). Clinical data and 
resource use were determined by literature/experts. Efﬁ cacy assessment was based on 
the outcome measure “relapses avoided.” RESULTS: Total discounted costs for all 
Austrian MS-patients on IFNb-therapy (incl. testing) from a health care system’s 
perspective amount to c187,764,180 for 5 years. Total costs for all MS-patients 
without testing amount to c176,331,610. The difference of costs between tested 
patients, and therefore switching, and not tested patients values c11,432,570. Con-
sidering all IFNb-treated patients and a time horizon of 5 years 1400 relapses can be 
avoided. Testing for NAB leads to costs per relapse avoided of c24,383p.a. versus 
c27,569p.a. when no tests are done resulting in a difference of c3,186 per patient in 
favour of NAB-testing. CONCLUSIONS: General NAB-testing in MS-patients on 
IFNb-therapy is reasonable and cost-effective. Patients switching to effective and more 
expensive alternatives do not account for higher health care costs. Furthermore, less 
relapses increase QoL.
PND15
PATIENT CHARACTERISTICS AND CHARGES ASSOCIATED WITH 
EMERGENCY DEPARTMENT VISITS AMONG PATIENTS WITH A 
DIAGNOSIS OF RESTLESS LEGS SYNDROME
Meyers J, Candrilli S
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: Restless legs syndrome (RLS) affects 2 to 15% of the US population. 
Limited data exist on patient characteristics and charges associated with emergency 
department (ED) visits among patients with RLS. METHODS: Data from the 2007 
Healthcare Cost and Utilization Project’s Nationwide Emergency Department Sample 
were used. Patients were selected for inclusion if they had a diagnosis of RLS (ICD-
9-CM code 333.94). Study measures included patient demographics and charges 
associated with the ED visit. Study measures were reported separately for patients 
with a primary versus secondary RLS diagnosis. Among patients with a secondary 
RLS diagnosis, the most common primary diagnoses were reported. RESULTS: A total 
of 6133 patients with a primary RLS diagnosis and 140,931 patients with a secondary 
RLS diagnosis were identiﬁ ed. Common primary diagnoses among patients with a 
secondary RLS diagnosis included respiratory symptoms (7.0%), general symptoms 
(4.6%), and pneumonia (3.7%). Mean (Std. Err.) age was 54.5 (0.6) years among 
patients with a primary diagnosis and 64.0 (0.3) years among patients with a second-
ary diagnosis. In both cohorts, over two-thirds of patients were female, the most 
common geographic regions were the South and Midwest, and Medicare was the most 
common primary payer (41.0% of patients with a primary diagnosis and 59.3% of 
patients with a secondary diagnosis). Over 90% of patients with a primary diagnosis 
had a routine discharge compared to only 26.6% of patients with a secondary diag-
nosis, and most patients with a secondary diagnosis were admitted to the facility as 
an inpatient. Mean (Std. Err.) charges were $816 ($48) for patients with a primary 
diagnosis and $2,043 ($62) for patients with a secondary diagnosis. CONCLUSIONS: 
This nationally representative study suggests that patients admitted to the ED with 
RLS accrue substantial costs during their visit. Further research is needed to more fully 
assess the total economic burden of the disease.
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OBJECTIVES: A reimbursement policy issued by the Federal Joint Committee in 
Germany to reassess the beneﬁ t of cholinesterase inhibitors every six months in order 
to receive continued coverage by the Statutory Health Insurance triggered an addi-
tional need to periodically assess the cost-beneﬁ t of galantamine in the treatment of 
mild-to-moderate Alzheimer’s disease (AD). An economic model speciﬁ cally designed 
for the purposes of such an assessment was developed using the most up-to-date 
IQWiG guidelines for cost-beneﬁ t assessment. METHODS: The model uses a discrete 
event simulation to predict the course of AD through changes in cognition, behavioral 
disturbance, and function over time, and compare the costs and beneﬁ ts of galan-
tamine versus no-drug treatment and ginkgo biloba. Clinical data were mainly derived 
from analyses of pooled data from clinical trials. Epidemiological and cost data were 
obtained from literature and public data sources. Costs (2009 c) from the perspective 
of the German Statutory Health Insurance were used. Both costs and beneﬁ ts were 
discounted at 5%. Sensitivity analyses were performed to assess the robustness of the 
model outcomes. RESULTS: Over a 10-year period, galantamine on average delays 
time to severe stage of the disease by 3.57 and 3.36 months, compared to no-drug 
treatment and ginkgo biloba, respectively. Galantamine also reduces time spent insti-
tutionalized by 2.34 and 2.21 months, compared to no-drug treatment and ginkgo 
biloba, respectively. The use of galantamine is projected to yield net savings of c3,978 
and c3,972 per patient compared to respective treatments. CONCLUSIONS: Our 
analyses suggest that compared to no-drug treatment and ginkgo biloba, treatment 
with galantamine not only improves clinical beneﬁ ts, but also achieves savings in 
health care costs associated with care for patients with mild-to-moderate AD in 
Germany.
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OBJECTIVES: To evaluate in the French setting the cost-effectiveness of memantine 
as adjunct therapy to Cholinesterase inhibitors (ChEI) compared to ChEI monother-
apy in Alzheimer’s disease (AD) patients. METHODS: A cost-effectiveness analysis 
employed a 3-state Markov model (“non-institutionalized,” “institutionalized” and 
“dead”) and compared the treatment alternatives in terms of time to nursing home 
admission, Quality Adjusted Life-years (QALYs), and costs over a 7-year time horizon. 
Annual transition probabilities between states were derived from two observational 
cohort studies: Lopez et al 2009 (US) for institutionalization probabilities and Helmer 
et al 2001 (FR) for death probabilities. Costs were valued from health care system 
and societal perspectives, and included cost of AD medications (French National 
